Drug Approval | March 21, 2023
Caplin receives USFDA approval for Rocuronium Bromide Injection
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
“One Earth, One Health” vision can become a reality only with active global collaboration where countries don’t think of only themselves, but of collective global outcomes
Proposed combination enhances Pfizer’s position as a leading company in oncology
The inspection concluded with no observations
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
Subscribe To Our Newsletter & Stay Updated
